Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACIU NASDAQ:HURA NASDAQ:NBTX NASDAQ:TNYA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$2.18-1.1%$2.15$1.43▼$3.98$218.49M1.61155,112 shs93,427 shsHURATuHURA Biosciences$2.41-4.6%$2.68$1.80▼$8.40$120.31M-0.1303,009 shs342,801 shsNBTXNanobiotix$9.24+6.0%$7.05$2.76▼$10.59$442.73M0.4711,789 shs11,485 shsTNYATenaya Therapeutics$1.32-6.1%$0.88$0.36▼$4.01$214.32M3.063.00 million shs2.50 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune-3.51%+7.84%+2.80%0.00%-26.42%HURATuHURA Biosciences-1.18%-6.67%+9.57%-7.35%+251,999,900.00%NBTXNanobiotix+1.93%-2.57%+18.02%+81.27%+64.34%TNYATenaya Therapeutics+3.70%+23.89%+109.30%+102.75%-39.39%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$2.18-1.1%$2.15$1.43▼$3.98$218.49M1.61155,112 shs93,427 shsHURATuHURA Biosciences$2.41-4.6%$2.68$1.80▼$8.40$120.31M-0.1303,009 shs342,801 shsNBTXNanobiotix$9.24+6.0%$7.05$2.76▼$10.59$442.73M0.4711,789 shs11,485 shsTNYATenaya Therapeutics$1.32-6.1%$0.88$0.36▼$4.01$214.32M3.063.00 million shs2.50 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune-3.51%+7.84%+2.80%0.00%-26.42%HURATuHURA Biosciences-1.18%-6.67%+9.57%-7.35%+251,999,900.00%NBTXNanobiotix+1.93%-2.57%+18.02%+81.27%+64.34%TNYATenaya Therapeutics+3.70%+23.89%+109.30%+102.75%-39.39%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACIUAC Immune 3.00Buy$10.00359.56% UpsideHURATuHURA Biosciences 3.40Buy$12.67426.68% UpsideNBTXNanobiotix 2.50Moderate Buy$8.00-13.37% DownsideTNYATenaya Therapeutics 3.00Buy$6.25375.29% UpsideCurrent Analyst Ratings BreakdownLatest TNYA, ACIU, HURA, and NBTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025ACIUAC ImmuneBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.009/2/2025TNYATenaya TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.008/27/2025TNYATenaya TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.008/7/2025TNYATenaya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.006/23/2025HURATuHURA BiosciencesBrookline Capital ManagementSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 9/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACIUAC Immune$31.02M7.04N/AN/A$1.29 per share1.69HURATuHURA BiosciencesN/AN/AN/AN/A$0.34 per shareN/ANBTXNanobiotix$39.18M11.30N/AN/A($1.51) per share-6.12TNYATenaya TherapeuticsN/AN/AN/AN/A$1.07 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACIUAC Immune-$57.83M-$0.58N/AN/AN/A-174.94%-49.35%-23.16%11/4/2025 (Estimated)HURATuHURA Biosciences-$21.68MN/A0.00∞N/AN/A-248.79%-150.83%10/6/2025 (Estimated)NBTXNanobiotix-$73.73MN/A0.00N/AN/AN/AN/AN/A9/17/2025 (Estimated)TNYATenaya Therapeutics-$111.13M-$0.96N/AN/AN/AN/A-93.83%-75.66%11/5/2025 (Estimated)Latest TNYA, ACIU, HURA, and NBTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025HURATuHURA Biosciences-$0.14-$0.21-$0.07-$0.21N/AN/A8/6/2025Q2 2025TNYATenaya Therapeutics-$0.20-$0.14+$0.06-$0.14N/AN/A8/5/2025Q2 2025ACIUAC Immune-$0.20-$0.25-$0.05-$0.25$1.98 million$1.65 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACIUAC ImmuneN/AN/AN/AN/AN/AHURATuHURA BiosciencesN/AN/AN/AN/AN/ANBTXNanobiotixN/AN/AN/AN/AN/ATNYATenaya TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACIUAC ImmuneN/A1.331.33HURATuHURA BiosciencesN/A0.830.83NBTXNanobiotixN/A1.041.04TNYATenaya TherapeuticsN/A6.006.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACIUAC Immune51.36%HURATuHURA Biosciences0.62%NBTXNanobiotix38.81%TNYATenaya Therapeutics90.54%Insider OwnershipCompanyInsider OwnershipACIUAC Immune4.60%HURATuHURA Biosciences0.20%NBTXNanobiotix3.45%TNYATenaya Therapeutics48.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACIUAC Immune140100.41 million95.79 millionOptionableHURATuHURA BiosciencesN/A50.05 million49.95 millionN/ANBTXNanobiotix10047.94 million46.29 millionNot OptionableTNYATenaya Therapeutics110162.98 million83.69 millionOptionableTNYA, ACIU, HURA, and NBTX HeadlinesRecent News About These CompaniesNuveen LLC Purchases New Shares in Tenaya Therapeutics, Inc. $TNYASeptember 9 at 3:08 AM | marketbeat.comTenaya Therapeutics' (TNYA) "Buy" Rating Reiterated at HC WainwrightSeptember 4, 2025 | marketbeat.comTenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare ConferenceSeptember 2, 2025 | globenewswire.comTenaya Therapeutics Reports Interim Data from Largest Pediatric MYBPC3-Associated HCM Study Highlighting Urgent Need for Novel TherapeuticsAugust 31, 2025 | quiverquant.comQTenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025August 31, 2025 | globenewswire.comTenaya Therapeutics (NASDAQ:TNYA) Receives "Buy" Rating from HC WainwrightAugust 29, 2025 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Tenaya Therapeutics (NASDAQ:TNYA)August 29, 2025 | americanbankingnews.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Average Recommendation of "Buy" from AnalystsAugust 28, 2025 | marketbeat.comFaraz Ali Sells 14,533 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) StockAugust 20, 2025 | marketbeat.comTenaya Therapeutics Reports Q2 2025 Financial ResultsAugust 14, 2025 | tipranks.comWhat is Leerink Partnrs' Estimate for TNYA FY2025 Earnings?August 11, 2025 | marketbeat.comQ3 EPS Estimate for Tenaya Therapeutics Lifted by AnalystAugust 11, 2025 | marketbeat.comWall Street Zen Upgrades Tenaya Therapeutics (NASDAQ:TNYA) to HoldAugust 10, 2025 | marketbeat.comTenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth ConferenceAugust 8, 2025 | globenewswire.comTenaya Therapeutics reports Q2 EPS (14c), consensus (19c)August 7, 2025 | msn.comTenaya (TNYA) Q2 Loss Narrows 59%August 7, 2025 | fool.comTenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 6, 2025 | globenewswire.comTenaya Therapeutics stock rises after positive safety reviews for heart gene therapiesJuly 30, 2025 | investing.comTenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as DesignedJuly 30, 2025 | globenewswire.comTNYA - Tenaya Therapeutics Inc Dividends - MorningstarJuly 8, 2025 | morningstar.comMTNYA - Tenaya Therapeutics Inc Trailing Returns - MorningstarJuly 8, 2025 | morningstar.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTNYA, ACIU, HURA, and NBTX Company DescriptionsAC Immune NASDAQ:ACIU$2.18 -0.02 (-1.09%) As of 03:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.TuHURA Biosciences NASDAQ:HURA$2.40 -0.12 (-4.56%) As of 03:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.Nanobiotix NASDAQ:NBTX$9.24 +0.53 (+6.03%) As of 03:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.Tenaya Therapeutics NASDAQ:TNYA$1.32 -0.09 (-6.07%) As of 03:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Casey’s General Stores: Investors Win With CASY at the Bat Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t 2 Small-Cap Dividend-Paying Retailers to Buy and Hold for 2026 What August Labor Data Means for the S&P 500 in September Take the Money and Run: Strategy Stock Looks Tapped Out Why CAVA Is the Dip Buy to Outperform Chipotle Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
